Molecular genetic diagnostics of clear cell renal cell carcinoma

Background. On the pace of growth in Russia, renal carcinoma takes the 1st place. Approximately one third of patients at time of diagnosis have distant metastases, and relapse of the disease occurs in 30–40 %. Renal carcinoma does not manifest until later stage of the disease. More than in 50 % of cases renal carcinoma is revealed occasionally. Therefore, development of methods for quick and efficient diagnosis of the tumor is actual.

Materials and methods. The level of messenger RNA expression for several genes was studied in the surgical material of paired samples (normal tissue and a malignant renal carcinoma). Quantification of gene expression was performed by using real-time polymerase chain reaction on Step One Plus instrument (Applied Biosystems, USA) by using TaqMan® Gene Expression Assays kits (Applied Biosystems, USA).

Results. As a result of screening analysis of 200 genes expression in paired samples of renal carcinoma/normal renal tissue we selected 5 genes showing the highest frequency of increased expression in stages I–III of the development of clear renal cell carcinoma: CA9, EGLN3, HIG2, NDUFA4L2, STC2.

Conclusion. As a result of the expression study we developed a new panel, including CA9, HIG2 and STC2 genes which has high sensitivity (96.8 %) and specificity (92.9 %) for differential diagnosis of the early clear cell renal cell carcinoma on the basis of determining the level of messenger RNA expression by real-time polymerase chain reaction. This approach allows you to diagnose clear cell renal cell carcinoma quickly (within 1 day), and differentiate it from other types of renal cell cancer. In addition, it opens the possibility of non-invasive diagnosis of renal carcinoma in the future.

1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: Издательская группа РОНЦ, 2014. 226 с. [Statistics of malignant tumors in Russia and CIS countries in 2012. Eds. by: М.I. Davydov, Е.М. Аksel’. Мoscow: Izdatel’skaya gruppa RONTS, 2014. 226 p. (In Russ.)].

2. Ljungberg B., Bensalah K., Bex A. et al. Guidelines on renal cell carcinoma. European association of urology, 2014. 70 p.

3. Caoili E.M., Davenport M.S. Role of percutaneous needle biopsy for renal masses. Semin Intervent Radiol 2014;31(1):20–6. DOI: 10.1055/s-0033-1363839. PMID: 24596436.

4. Vetterlein M.W., Jindal T., Becker A. et al. Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investig Clin Urol 2016;57(4):231–9. DOI: 10.4111/icu.2016.57.4.231. PMID: 27437532.

5. Marconi L., Dabestani S., Lam T.B. et al. systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69(4):660–73. DOI: 10.1016/j.eururo.2015.07.072. PMID: 26323946.

6. Tostain J., Li G., Gentil-Perret A., Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer 2010;46(18):3141–8. DOI: 10.1016/j.ejca.2010.07.020. PMID: 20709527.

7. Luo W., Hu H., Chang R. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011;145(5):732–44. DOI: 10.1016/j.cell.2011.03.054. PMID: 21620138.

8. Gimm T., Wiese M., Teschemacher B. et al. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1 FASEB 2010;24(11):4443–58. DOI: 10.1096/fj.10-159806. PMID: 20624928.

9. Seo T., Konda R., Sugimura J. et al. Expression of hypoxia-inducible protein 2 in renal cell carcinoma: a promising candidate for molecular targeting therapy. Oncol Lett 2010;1(4):697–701. DOI: 10.3892/ol_00000122. PMID: 22966366.

10. Fredlund E., Ovenberger M., Borg K., Påhlman S. Transcriptional adaptation of neuroblastoma cells to hypoxia. Biochem Biophys Res Commun 2008;366(4):1054–60. DOI: 10.1016/j.bbrc.2007.12.074. PMID: 18155155.

11. Apanovich N.V., Poyarkov S.V., Peters M.V. et al. The differential gene expression in clear cell renal cell carcinoma and biomarker development. Eur Hum Gen 2015;23(Suppl 1):446.

12. Minton D.R., Fu L., Mongan N.P. et al. Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma. Clin Cancer Res 2016;22(11):2791–801. DOI: 10.1158/1078-0432.CCR-15-1511. PMID: 26783287.

13. Law A.Y., Wong C.K. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 2010;316(20):3425–34. DOI: 10.1016/j.yexcr.2010.06.026. PMID: 20619259.

14. Yeung B.H., Law A.Y., Wong C.K. Evolution and roles of stanniocalcin. Mol Cell Endocrinol 2012;349(2):272–80. DOI: 10.1016/j.mce.2011.11.007. PMID: 22115958.

15. Fisher K.E., Yin-Goen Q., Alexis D. et al. Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Mod Pathol 2014;27(2)222–30. DOI: 10.1038/modpathol.2013.140. PMID: 23887297.

16. Li G., Bilal I., Gentil-Perret A. et al. CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Urol Oncol 2012;30(4):463–8. DOI: 10.1016/j.urolonc.2010.04.014. PMID: 20822935.

17. Girgis A.H., Iakovlev V.V., Beheshti B. et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012;72(20):273–84. DOI: 10.1158/0008-5472.CAN-12-0656. PMID: 22926558.

18. The Principles of Clinical Cytogenetics Eds. by: S.L. Gersen, M.B. Keagle. NY: Springer, 2013. Рp. 380–381.

19. Davis C.F., Ricketts C.J., Wang M. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014;26(3):319–30. DOI: 10.1016/j.ccr.2014.07.014. PMID: 25155756.